Active Studies
Study Status
Principal Investigator
Protocol Title
Sponsor
Open for Enrollment
Maneesh Jain, MD
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fam-Trastuzumab Deruxtecan-Nxki (T-DXd) as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma
Daiichi Sankyo, Inc.
Open for Enrollment
Gail Kerr, MD
Identifying Novel Biomarkers of Disease Progression in Rheumatoid Arthritis-Associated Interstitial Lung Disease
University of Pittsburgh (Foundation award)
Open for Enrollment
Mary Lee, MD
Towards treatment for the complex patient: investigations of low-intensity focused ultrasound.
National Institute of Health
Open for Enrollment
Ping Li, MD
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals, Inc.
Open for Enrollment
Dalia Mobarek, MD
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (the “Study”).
Johnson & Johnson
Open for Enrollment
Atoosa Rabiee, MD
ML44719, A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
Genentech
Open for Enrollment
Sabyasachi Sen, MD, PhD
Role of Empagliflozin in African American Veterans with Non-Diabetic Chronic Kidney Disease
Boehringer Ingelheim
Open for Enrollment
Matthew Tuck, MD
A Primary Role for the Circulatory Microenvironment in African American Prostate Cancer Disparities
US Department of Defence
Open for Enrollment
Jose Vargas, MD
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis due to Non-Alcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Akero Therapeutics, Inc.
